In the News

Catalyst Pharmaceuticals Announces Positive Top-Line Phase 3 Data From Pivotal Firdapse Clinical Trial

by Traci Bratton

October 03, 2014
Print
Email

Shin J. Oh, MD, Distinguished Professor Emeritus of Neurology, University of Alabama at Birmingham, School of Medicine, stated, "I am extremely pleased to see the results from the first ever Phase 3 controlled study in this LEMS patient population, which confirmed a positive treatment effect for Firdapse. When combined with the favorable safety profile, the results indicate that the drug should become the standard of care in treating LEMS patients once approved by the FDA."

http://www.drugs.com/clinical_trials/catalyst-pharmaceuticals-announces-positive-top-line-phase-3-data-pivotal-firdapse-clinical-trial-16651.html

back to top

Media Policy Guidelines

Marketing and Communications

UAB Home

The University of Alabama at Birmingham

1720 2nd Ave South

Birmingham, AL 35294

Public Relations: (205) 934-3884

Media Specialist On Call: (205) 934-3411

Contact UAB
|
|
A-Z Site Index
|
Privacy
|
Terms of Use
|

UAB is an Equal Employment/Equal Educational Opportunity Institution dedicated to providing equal opportunities and equal access to all individuals regardless of race, color, religion, ethnic or national origin, sex (including pregnancy), genetic information, age, disability, religion, sexual orientation, gender identity, gender expression, and veteran’s status. As required by Title IX, UAB prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to UAB’s Assistant Vice President and Senior Title IX Coordinator. The Title IX notice of nondiscrimination is located at uab.edu/titleix.